Patient-centric insights for
Pharmaceutical and Clinical
Patient-centric insights for Pharmaceutical and Clinical applications.
We can now access patient-specific response data, earlier than ever before. Our PMAs allow us to screen compounds at the earliest stages, to optimize resources and focus on the most meaningful targets.
Our PMAs create a unique opportunity to compare responses to drugs in development and well-established Standard of Care therapies within the same patient samples. We are also able to find novel applications for approved treatments by assessing responses across a range of indications, unlocking label expansion opportunities.
Through partnerships with cancer centers, our technology provides actionable data on patients’ likely response to a wide array of treatments, simultaneously, within seven days. Our reach goes beyond the Standard of Care and can also help patients with limited therapeutic options to identify the most promising clinical trials.